Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HA131
- Development stage
- Phase 2
- Lead developer
- CSPC Pharmaceutical Group
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Hepatic Arterial Infusion
01
Overview
HA131 is a drug formulated as Paclitaxel Cationic Liposomes for injection. It exerts a dual anti-tumor action through the cytotoxic effect of paclitaxel and the targeting capabilities of cationic liposomes. The cationic liposomes target negatively charged tumor neovascular endothelial cells, blocking the supply of nutrients and inducing apoptosis of tumor cells. It is being investigated for the first-line treatment of gastrointestinal cancer with liver metastases.
- Other names
- Paclitaxel Cationic Liposomes for injection
02
Targets
TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on HA131.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HA131.